In tumours where MYCN, PRMT5 and E2F1 are expressed at lower levels and splicing activity is similarly reduced, we suggest that other PRMT5 independent mechanisms contribute to the malignant phenotype. This evidence concerns the gene E2F1 and neoplasm.